NUWE

Nuwellis is a going-concern medical-device microcap whose own 10-K states it had capital to fund operations only 'through the end of the second quarter of 2026' and 'will need to raise additional capital to fund our operations through the end of fiscal year 2026.' That is not a forward risk — it is a here-and-now solvency gap. FY2025 operating cash flow was -$10.8M against just $1.08M of cash (down 78.7% YoY) and $2.62M of stockholders' equity (down 59.8%). The math is unforgiving: the cash on hand covers roughly five weeks of the current burn, so a dilutive raise is not a possibility but a near-certainty, and management explicitly warns stockholders 'may suffer dilution.'

The business underneath the balance sheet does not justify a rescue premium. Revenue is structurally flat-to-down — $8.86M (FY2023) → $8.74M (FY2024) → $8.27M (FY2025), a -5.4% YoY decline — and the company concedes near-term prospects are 'highly dependent on revenues from a single product, the Aquadex System,' with 'no other commercial products at this time.' Gross margin is a respectable 62%, but operating margin is -134% and net margin is -212%; the model has never been profitable across five disclosed years of double-digit-million losses. ROE of -668% and an accumulated deficit of -$316M underline that capital poured in has been destroyed, not compounded.